Two Biotech Beauties for the Long Run

Shares of Celgene and Gilead benefited Monday from favorable clinical trials of drugs. Expect more good news for the stocks.

Celgene and Gilead Sciences are two very different drug makers developing very different medications for very different patients.

But both companies released clinical trials results over the weekend that wowed investors. And at current valuations, both biotech stocks offer value to investors looking for companies able to grow sales and profit at a robust pace over the next few years.